Hydrothermal Fabrication of High Specific Surface Area Mesoporous
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Sodium Dodecyl Sulfate
Catalog Number: 102918, 190522, 194831, 198957, 811030, 811032, 811033, 811034, 811036 Sodium dodecyl sulfate Structure: Molecular Formula: C12H25NaSO4 Molecular Weight: 288.38 CAS #: 151-21-3 Synonyms: SDS; Lauryl sulfate sodium salt; Dodecyl sulfate sodium salt; Dodecyl sodium sulfate; Sodium lauryl sulfate; Sulfuric acid monododecyl ester sodium salt Physical Appearance: White granular powder Critical Micelle Concentration (CMC): 8.27 mM (Detergents with high CMC values are generally easy to remove by dilution; detergents with low CMC values are advantageous for separations on the basis of molecular weight. As a general rule, detergents should be used at their CMC and at a detergent-to-protein weight ratio of approximately ten. 13,14 Aggregation Number: 62 Solubility: Soluble in water (200 mg/ml - clear, faint yellow solution), and ethanol (0.1g/10 ml) Description: An anionic detergent3 typically used to solubilize8 and denature proteins for electrophoresis.4,5 SDS has also been used in large-scale phenol extraction of RNA to promote the dissociation of protein from nucleic acids when extracting from biological material.12 Most proteins bind SDS in a ratio of 1.4 grams SDS to 1 gram protein. The charges intrinsic to the protein become insignificant compared to the overall negative charge provided by the bound SDS. The charge to mass ratio is essentially the same for each protein and will migrate in the gel based only on protein size. Typical Working Concentration: > 10 mg SDS/mg protein Typical Buffer Compositions: SDS Electrophoresis -
Sodium Dodecyl Sulfate-Coated Alumina and C18 Cartridge for The
J. Braz. Chem. Soc., Vol. 19, No. 8, 1523-1530, 2008. Printed in Brazil - ©2008 Sociedade Brasileira de Química 0103 - 5053 $6.00+0.00 Article Sodium Dodecyl Sulfate-Coated Alumina and C18 Cartridge for the Separation and Preconcentration of Cationic Surfactants Prior to their Quantitation by Spectrophotometric Method Mohammad Ali Karimi,*,a,b Reza Behjatmanesh-Ardakani,b Ali Aghaei Goudi b and Sara Zali b aDepartment of Chemistry, Faculty of Science, Payame Noor University (PNU), Sirjan, Iran bDepartment of Chemistry, Faculty of Science, Payame Noor University (PNU), Ardakan, Iran Um novo método de extração em fase sólida foi desenvolvido para separar e pré-concentrar traços de tensoativos catiônicos, tais como, brometo de dodeciltrimetilamônio (DTAB), brometo de cetiltrimetilamônio (CTAB) e cloreto de cetilpiridínio (CPC). Esse método é baseado na sorção do tensoativo aniônico (AS−), dodecilssulfato de sódio (SDS), sobre a superfície de γ-alumina, + enquanto um cartucho C18 é utilizado para a pré-concentração dos tensoativos catiônicos (CS ). O método espectrofotométrico, utilizado para a determinação dos tensoativos catiônicos, baseia-se na competição entre o corante catiônico, azul de metileno (MB+), e o CS+, para associação e formação do complexo SDS. O íon complexo formado (MB+) pode ser quantitativamente substituído pelo CS+, levando a um aumento da absorvância medida em 662 nm. Foram estabelecidas ótimas condições experimentais para a separação, pré-concentração e determinação dos tensoativos catiônicos. Sob essas condições otimizadas, realizou-se a pré-concentração (2×) e os resultados mostraram que a determinação do CPC, DTAB e CTAB poderia ser realizada nas faixas de concentração de 1×10-5-2×10-4, 4×10-5-5×10-4 and 5×10-5-5×10-4 mol L-1, respectivamente. -
Chemicals Used for Chemical Manufacturing Page 1 of 2
Chemicals used for Chemical Manufacturing Page 1 of 2 Acetic Acid (Glacial, 56%) Glycol Ether PMA Acetone Glycol Ether PNB Acrylic Acid Glycol Ether PNP Activated Carbon Glycol Ether TPM Adipic Acid Glycols Aloe Vera Grease Aluminum Stearate Gum Arabic Aluminum Sulfate Heat Transfer Fluids Amino Acid Heptane Ammonium Acetate Hexane Ammonium Bicarbonate Hydrazine Hydrate Ammonium Bifluoride Hydrochloric Acid (Muriatic) Ammonium Chloride Hydrogen Peroxide Ammonium Citrate Hydroquinone Ammonium Hydroxide Hydroxylamine Sulfate Ammonium Laureth Sulfate Ice Melter Ammonium Lauryl Sulfate Imidazole Ammonium Nitrate Isobutyl Acetate Ammonium Persulfate Isobutyl Alcohol Ammonium Silicofluoride Calcium Stearate Dipropylene Glycol Isopropanolamine Ammonium Sulfate Carboxymethylcellulose Disodium Phosphate Isopropyl Acetate Antifoams Caustic Potash D'Limonene Isopropyl Alcohol Antifreeze Caustic Soda (All Grades) Dodecylbenzene Sulfonic Acid Isopropyl Myristate Antimicrobials Caustic Soda (Beads, Prills) (DDBSA) Isopropyl Palmitate Antimony Oxide Cetyl Alcohol Dowfrost Itaconic Acid Aqua Ammonia Cetyl Palmitate Dowfrost HD Jojoba Oil Ascorbic Acid Chlorine, Granular Dowtherm SR-1 Keratin Barium Carbonate Chloroform Dowtherm 4000 Lactic Acid Barium Chloride Chromic Acid EDTA Lanolin Beeswax Citric Acid (Dry and Liquid) EDTA Plus Lauric Acid Bentonite Coal Epsom Salt Lauryl Alcohol Benzaldehyde Cocamide DEA Ethyl Acetate Lecithin Benzoic Acid Copper Nitrate Ethyl Alcohol (Denatured) Lime Benzyl Alcohol Copper Sulfate Ethylene Glycol Linoleic Acid Bicarbonate -
Sodium Lauryl Sulfate 1 Sodium Lauryl Sulfate
Sodium lauryl sulfate 1 Sodium lauryl sulfate Sodium dodecyl sulfate Identifiers [1] CAS number 151-21-3 [2] ATC code A06 AG11 Properties Molecular formula NaC H SO 12 25 4 Molar mass 288.38 g mol−1 Density 1.01 g/cm³ Melting point 206 °C [3] (what is this?) (verify) Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) Infobox references Sodium lauryl sulfate (SLS), sodium laurilsulfate or sodium dodecyl sulfate (SDS or NaDS) (C H SO Na) is 12 25 4 an anionic surfactant used in many cleaning and hygiene products. The molecule has a tail of 12 carbon atoms, attached to a sulfate group, giving the molecule the amphiphilic properties required of a detergent. SLS is a highly effective surfactant and is used in any task requiring the removal of oily stains and residues. For example, it is found in higher concentrations with industrial products including engine degreasers, floor cleaners, and car wash soaps. It is used in lower concentrations with toothpastes, shampoos, and shaving foams. It is an important component in bubble bath formulations for its thickening effect and its ability to create a lather. Research showed that SLS is not carcinogenic when either applied directly to skin or consumed.[4] It has however been shown to irritate the skin of the face with prolonged and constant exposure (more than an hour) in young adults.[5] A clinical study found SLS toothpaste caused a higher frequency of aphthous ulcers than both cocoamidopropyl betaine or a detergent-free paste, on 30 patients with frequent occurrences of such ulcers.[6] A clinical study comparing toothpastes with and without SLS found that it had no significant effect on ulcer patterns.[7] Sodium lauryl sulfate 2 Applications SLS is a highly effective surfactant and is used in any task requiring the removal of oily stains and residues. -
Hazard Communication Chemical Inventory Form
Hazard Communication Chemical Inventory Form ESTIM. CAS STATE QTY. USAGE ROOM SDS DATE OF CHEMICAL NAME COMMON NAME MANUFACTURER NUMBER S,L,G ON HAND PER YEAR CAMPUS NO. DEPARTMENT ? INV. 90wGear Oil NAPA L 5 gal 1 Gal AVC Auto shop Facilities Y 4/2/2018 Acetylene Gas Airgas USA G 33 cu ft 4 cu ft AVC Auto shop Facilities Y 4/2/2018 Antifreeze (Ethylene Glycol) NAPA L 1 gal 2 Gal AVC Auto shop Facilities Y 4/2/2018 Brakleen CRC Industries G 8 cans 12 Cans AVC Auto shop Facilities Y 4/2/2018 CBC Plus Bowl Cleaner ECOLAB L 60 72 AVC Auto shop Facilities Y 4/2/2018 DOT3 Brake Fluid NAPA Mixture L 1 QT 1 QT AVC Auto shop Facilities Y 4/2/2018 Hydraulic Oil NAPA L 10 gal 4 gal AVC Auto shop Facilities Y 4/2/2018 Motor Oil NAPA L 48 Qt 32 Qt AVC Auto shop Facilities Y 4/2/2018 Oxygen Gas Airgas USA G 33 cu ft 10 cu ft AVC Auto shop Facilities Y 4/2/2018 Toluidine Blue 2% Carolina 92-31-9 L 20mL 0mL AVC B112 Science SDS 1/22/2018 Isopropyl Alcohol 2-Propanol, Isopropanol JT Baker(Avantor) 67-63-0 L 75mL 5mL AVC B112 Science SDS 1/22/2018 Ammonium Molybdate ammonium molybdate(VI), tetrahydrate, molybdicFlinn acid 12027-67-7 S 15g 10g AVC B112 Science SDS 1/22/2018 Ammonium Chloride ammonium muriate, sal ammoniac Flinn 12125-02-9 S 40g 5g AVC B112 Science SDS 1/22/2018 Ethylene Glycol Anti-Freeze JT Baker(Avantor) 107-21-1 L 1.25L 10mL AVC B112 Science SDS 1/22/2018 Sodium Bicarbonate Baking Soda VWR (Wards) 144-55-8 S 1,020g 10g AVC B112 Science No 1/22/2018 Sodium Borate Borax VWR 1303-96-4 S 225g 10g AVC B112 Science SDS 1/22/2018 Calcium Metal -
Potassium-Magnesium Citrate Is an Effective Prophylaxis Against Recurrent Calcium Oxalate Nephrolithiasis
0022-5347/97/1586-2069$03.00/0 JOURNAL OF UROLOGY Vol. 158,2069-2073, December 1997 Copyright Q 1997 by AMERICANUROLOGICAL ASS~CIATION, INC. Printed in U.S.A. POTASSIUM-MAGNESIUM CITRATE IS AN EFFECTIVE PROPHYLAXIS AGAINST RECURRENT CALCIUM OXALATE NEPHROLITHIASIS BRUCE ETTINGER,* CHARLES Y. C. PAK, JOHN T. CITRON, CARL THOMAS, BEVERLEY ADAMS-HIJET AND ARLINE VANGESSEL From the Diuision of Research, Kaiser Permanente Medical Care Program, Oakland, California, the Department of Mineral Metabolism, Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, Department of Medicine, Kaiser Permanente Medical Center, Walnut Creek, California, Department of Urology, Kaiser Permanente Medical Center, San Francisco, California, and Kaiser Foundation Research Institute, Kaiser Foundation Hospitals, Oakland, California ABSTRACT Purpose: We examined the efficacy of potassium-magnesium citrate in preventing recurrent calcium oxalate kidney calculi. Materials and Methods: We conducted a prospective double-blind study of 64 patients who were randomly assigned to receive placebo or potassium-magnesium citrate (42 mEq. potassium, 21 mEq. magnesium, and 63 mEq. citrate) daily for up to 3 years. Results. New calculi formed in 63.6%of subjects receiving placebo and in 12.9%of subjects receiving potassium-magnesiumcitrate. When compared with placebo, the relative risk of treat- ment failure for potassium-magnesium citrate was 0.16 (95%confidence interval 0.05 to 0.46). potassium-magnesium citrate had a statistically significant effect (relative risk 0.10,95%confi- dence interval 0.03 to 0.36) even after adjustment for possible confounders, including age, pretreatment calculous event rate and urinary biochemical abnormalities. -
Sodium Laurilsulfate Used As an Excipient
9 October 2017 EMA/CHMP/351898/2014 corr. 1* Committee for Human Medicinal Products (CHMP) Sodium laurilsulfate used as an excipient Report published in support of the ‘Questions and answers on sodium laurilsulfate used as an excipient in medicinal products for human use’ (EMA/CHMP/606830/2017) * Deletion of the E number. Please see the corrected Annex for further details. 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. Sodium laurilsulfate used as an excipient Table of contents Executive summary ..................................................................................... 3 Introduction ................................................................................................ 4 Scientific discussion .................................................................................... 4 1. Characteristics ....................................................................................... 4 1.1 Category (function) ............................................................................................. 4 1.2 Properties........................................................................................................... 4 1.3 Use in medicinal products ..................................................................................... 5 1.4 Regulatory -
Laxatives for the Management of Constipation in People Receiving Palliative Care (Review)
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by UCL Discovery Laxatives for the management of constipation in people receiving palliative care (Review) Candy B, Jones L, Larkin PJ, Vickerstaff V, Tookman A, Stone P This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2015, Issue 5 http://www.thecochranelibrary.com Laxatives for the management of constipation in people receiving palliative care (Review) Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 BACKGROUND .................................... 2 OBJECTIVES ..................................... 4 METHODS ...................................... 4 RESULTS....................................... 7 Figure1. ..................................... 8 Figure2. ..................................... 9 Figure3. ..................................... 10 DISCUSSION ..................................... 13 AUTHORS’CONCLUSIONS . 14 ACKNOWLEDGEMENTS . 14 REFERENCES ..................................... 15 CHARACTERISTICSOFSTUDIES . 17 DATAANDANALYSES. 26 ADDITIONALTABLES. 26 APPENDICES ..................................... 28 WHAT’SNEW..................................... 35 HISTORY....................................... 35 CONTRIBUTIONSOFAUTHORS . 36 DECLARATIONSOFINTEREST . 36 SOURCESOFSUPPORT . 36 DIFFERENCES -
United States Patent (19) 11) Patent Number: 5,073,374 Mccarty 45 Date of Patent: Dec
United States Patent (19) 11) Patent Number: 5,073,374 McCarty 45 Date of Patent: Dec. 17, 1991 54 FAST DISSOLVING BUCCAL TABLET 1380171 1/1975 United Kingdom . 21888.43 10/1987 United Kingdom . 75 Inventor: John A. McCarty, Biscayne Park, 04342 7/1987 World Int. Prop. O. .......... 424/435 Fla. OTHER PUBLICATIONS 73 Assignee: Schering Corporation, Kenilworth, N. Kornbloom and Stoopak, J. Pharm. Sci., 62:43-49 (1973). (21 Appl. No.: 278,099 Kahn and Rooke, Mfg. Chemist & Aerosol News, pp. 22 Filed: Nov. 30, 1988 25-26 (Jan. 1976). 51 int. Cl. ........................ A61K9/20: A61K 47/00 Kahn and Rooke, J. Pharm. Pharmacol., 28:633-636 52 U.S. Cl. .................................... 424/435; 424/434; (1976). 424/464; 424/465; 514/777 Primary Examiner-Thurman K. Page 58 Field of Search ................ 424/434, 435, 465,499 Assistant Examiner-James M. Spear 56 References Cited Attorney, Agent, or Firm-Anita W. Magatti; James R. Nelson U.S. PATENT DOCUMENTS 4,059,686 1/1977 Tanaka et al. ........................ 424/19 57 ABSTRACT 4,226,848 10/1980 Naggi et al. .......................... 424/19 A fast dissolving buccal tablet for administering a medi 4,292.299 9/1981 Suzuki et al. ......................... 424/16 4,572,832 2/1986 Kigasawa et al. .................... 424/19 canent includes the active ingredient, a lubricant and a 4,755,386 7/1988 Hsiao et al. ......................... 424/435 water soluble sugar, such as sorbitol, combined such that the buccal tablet dissolves in about one minute. FOREIGN PATENT DOCUMENTS 275853 10/1973 France . 10 Claims, No Drawings 5,073,374 1 2 the patient from swallowing the dosage form. -
Cycle Stability and Hydration Behavior of Magnesium Oxide and Its Dependence on the Precursor-Related Particle Morphology
nanomaterials Article Cycle Stability and Hydration Behavior of Magnesium Oxide and Its Dependence on the Precursor-Related Particle Morphology Georg Gravogl 1,2, Christian Knoll 2,3 , Jan M. Welch 4, Werner Artner 5, Norbert Freiberger 6, Roland Nilica 6, Elisabeth Eitenberger 7, Gernot Friedbacher 7, Michael Harasek 3 , Andreas Werner 8, Klaudia Hradil 5, Herwig Peterlik 9, Peter Weinberger 2 , Danny Müller 2,* and Ronald Miletich 1 1 Department of Mineralogy and Crystallography, University of Vienna, Althanstraße 14, 1090 Vienna, Austria; [email protected] (G.G.); [email protected] (R.M.) 2 Institute of Applied Synthetic Chemistry, TU Wien, Getreidemarkt 9, 1060 Vienna, Austria; [email protected] (C.K.); [email protected] (P.W.) 3 Institute of Chemical, Environmental & Biological Engineering, TU Wien, Getreidemarkt 9, 1060 Vienna, Austria; [email protected] 4 Atominstitut, TU Wien, Stadionallee 2, 1020 Vienna, Austria; [email protected] 5 X-ray Center, TU Wien, Getreidemarkt 9, 1060 Vienna, Austria; [email protected] (W.A.); [email protected] (K.H.) 6 RHI-AG, Magnesitstraße 2, 8700 Leoben, Austria; [email protected] (N.F.); [email protected] (R.N.) 7 Institute of Chemical Technologies and Analytics, TU Wien, Getreidemarkt 9, 1060 Vienna, Austria; [email protected] (E.E); [email protected] (G.F.) 8 Institute for Energy Systems and Thermodynamics, TU Wien, Getreidemarkt 9, 1060 Vienna, Austria; [email protected] 9 Faculty of Physics, University of Vienna, Boltzmanngasse 5, 1090 Vienna, Austria; [email protected] * Correspondence: [email protected]; Tel.: +43-1-5880-1163-740 Received: 31 August 2018; Accepted: 2 October 2018; Published: 7 October 2018 Abstract: Thermochemical energy storage is considered as an auspicious method for the recycling of medium-temperature waste heat. -
Impact of a Drugs & Therapeutics Backgrounder on Docusate Utilization
Impact of a Drugs & Therapeutics Backgrounder on Docusate Utilization Darren Pasay, B.Sc.Pharm Drug Stewardship Pharmacist (Central Zone) [email protected] Disclosure I have no actual or potential conflict of interest in relation to this topic or presentation. Drug Stewardship in Alberta Health Services • Drug Stewardship (DS) Team established in 2012 • “The shared responsibility of Drugs & Safety Therapeutics Committee (DTC), prescribers, pharmacy and care units to ensure Sustainability medications are used in a manner that maximizes the effectiveness, safety and sustainability of care for our patients” Effectiveness • Research and project support Drugs & Therapeutics Backgrounders (DTBs) • Frontline staff wanted background and support on DTC/formulary issues1 • One page document, meant to enhance conversations with prescribers • Supported by content experts, based upon DTC directions • Published 6 times/year • Followed by 2 interactive webinars for each edition 1. Pasay Darren K, Chow Sheldon JS, Bresee Lauren C, Guirguis Micheal, Slobodan Jeremy. Assessment of current antimicrobial stewardship policies and resources: a focus group project. Healthcare Infection 2015; 20: 7–15. Docusate • Over-the-counter stool softener • It is clear, based on published peer-reviewed literature, that docusate is ineffective for the prevention or treatment of constipation • Open listed on AHS Provincial Drug Formulary • Limited coverage on Alberta Drug Benefit List (palliative care only) Docusate DTB • Preliminary work o ~ 2 million doses/year dispensed • Influences o Some LTC sites have eliminated o Engrained in practice use already • Part of pharmacy, medicine, nursing curriculums • Order sets, Pre-printed care • What are the costs of? orders (PPCO) o Procurement o Seen as innocuous, safe o Processing, dispensing o Medication administration o Medication burden BOTTOM LINE: Docusate is no more effective than placebo for the prevention and treatment of constipation. -
United States Patent Office Patented Nov
3,539,306 United States Patent Office Patented Nov. 10, 1970 2 properties of quick activity, durable effect and storage 3,539,306 PROCESS FOR THE PREPARATION Stability, and that, therefore, the same can provide an ex OF HYDROTALCITE cellent, ideal antacid. Teruhiko Kumura and Norio Imataki, Takamatsu-shi, Hydrotalcite is known as a mineral having a chemical Katuyuki Hasui, Kagawa-ken, and Takeo Inoue and 5 Structure of the formula Kimiaki Yasutomi, Nagao-machi, Kagawa-ken, Japan, assignors to Kyowa Chemical Industry Co., Ltd., Tokyo, MgAl(OH) 16CO3 4HO O Al2O3 6MgO CO2: 12H2O Japan, a corporation of Japan No Drawing. Filed July 21, 1967, Ser. No. 654,977 which has been naturally produced in only very limited Claims priority, application Japan, July 25, 1966, areas as Norway and Ural. Also a process for the syn 41/48,349; July 17, 1967, 42/45,658 O thesis of hydrotalcite was disclosed, which comprises add Int. C. COf 5/00, 7/00, A61k 27/06 ing Dry Ice or ammonium carbonate to a mixture of U.S. C. 23-315 4 Claims magnesium oxide and y-alumina or the thermal decom position product from of magnesium nitrate and aluminum nitrate, and thereafter maintaining the system at tempera ABSTRACT OF THE DISCLOSURE, tures below 325 C. and under elevated pressures of total A process for the preparation of hydrotalcite which 2,000-20,000 p.s.i. (Roy et al.: American Journal of comprises mixing an alumium component such as alumi Science 251, 350-353 (1953)). However this process is num Salt With a magnesium component such as magnesium obviously unpractical for industrial scale production of Salt in an aqueous medium in the presence of carbonate hydrotalcite, because the reaction system must be main ion at a pH of at least 8 and thereafter recovering the 20 tained under considerably high pressures.